Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 6/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21411122 | 0.93 | NPFFR1 (0.52) | NPFFR1NPFFR2CYP2D6AKT1CHRM2 | |
| SCHEMBL21410757 | 0.81 | NPFFR1 (0.51) | NPFFR1NPFFR2CYP2D6AKT1CHRM2 | |
| SCHEMBL31711988 | 0.80 | NPFFR1 (0.50) | NPFFR1NPFFR2CYP2D6AKT1CHRM2 | |
| SCHEMBL14722834 | 0.80 | NPFFR1 (0.50) | NPFFR1NPFFR2CYP2D6CHRM2CHRM3 | |
| SCHEMBL8430714 | 0.80 | CYP3A4 (0.49) | NPFFR1NPFFR2CYP2D6AKT1ALDH1A1 | |
| SCHEMBL16196924 | 0.73 | AKT1 (0.46) | NPFFR1NPFFR2CYP2D6AKT1ALDH1A1 | |
| SCHEMBL1997960 | 0.73 | NPFFR1 (0.58) | NPFFR1NPFFR2CYP2D6CHRM2CHRM3 | |
| SCHEMBL2158292 | 0.71 | DRD2 (0.53) | NPFFR1NPFFR2CYP2D6CHRM2CHRM3 | |
| SCHEMBL14728238 | 0.71 | NPFFR1 (0.64) | NPFFR1NPFFR2CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL6703813 | 0.71 | NPFFR1 (0.61) | NPFFR1NPFFR2CYP2D6CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | NPFFR1 4836/4885NPFFR2 4854/4885CYP2D6 4691/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | NPFFR1 4675/4885NPFFR2 4749/4885CYP2D6 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.